Baillie Gifford & Co
FOLD

Baillie Gifford & Co’s Amicus Therapeutics FOLD Stock Holding History

Baillie Gifford & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-538
Closed -$5.97K – 351
2023
Q1 		$5.97K Hold
538
– – ﹤0.01% 412
2022
Q4 		$6.57K Hold
538
– – ﹤0.01% 435
2022
Q3 		$6K Hold
538
– – ﹤0.01% 437
2022
Q2 		$6K Hold
538
– – ﹤0.01% 445
2022
Q1 		$5K Hold
538
– – ﹤0.01% 464
2021
Q4 		$6K Hold
538
– – ﹤0.01% 473
2021
Q3 		$5K Hold
538
– – ﹤0.01% 479
2021
Q2 		$5K Hold
538
– – ﹤0.01% 462
2021
Q1 		$5K Buy
538
+3
+0.6% +$46 ﹤0.01% 433
2020
Q4 		$12K Buy
+535
New +$10.9K ﹤0.01% 366

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co's FOLD Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 538 shares — an estimated $5.97K sold.

Baillie Gifford & Co first reported a position in FOLD in Q4 2020 and held it in 10 quarters. The position peaked at $12K in Q4 2020. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 538 Amicus Therapeutics shares in Q2 2023, an estimated $5.97K.
  • Baillie Gifford & Co first reported a position in Amicus Therapeutics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Amicus Therapeutics position peaked at $12K in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.